Example: Heart Attack

Search clinical trials for: Imatinib

Total 684 results

NCT02413736

Recruiting

Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST

Conditions: Sarcoma
NCT01742299

Active, not recruiting

Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator

Conditions: GIST and CML
NCT02146846

Terminated

Population Pharmacokinetics of Imatinib in CML Patients in Iran

Conditions: Chronic Myelogenous Leukemia
NCT02177825

Terminated

Study of Imatinib Mesylate in Neurofibromatosis Type I Patients Aged 2 to 21 With Plexiform Neurofibromas

Conditions: Plexiform Neurofibromas
NCT02260505

Recruiting

Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST)

Conditions: Gastrointestinal Stromal Tumors; Resected Gastrointestinal Stromal Tumors; Non-metastatic; High Risk of Recurrence; KIT Gene Mutation
NCT00787384

Completed

Efficacy of Imatinib Mesylate in Hypereosinophilic Syndromes

Conditions: Hypereosinophilic Syndrome; Chronic Eosinophilic Leukemia; Chronic Idiopathic Hypereosinophilia
NCT04006769

Not yet recruiting

Entacapone Combination With Imatinib for Treatment of GIST

Conditions: Gastrointestinal Stromal Tumor, Malignant
NCT04422678

Not yet recruiting

The Safety & Efficacy of Imatinib for the Treatment of SARS-COV-2 Induced Pneumonia

Conditions: COVID-19
NCT01294202

Completed

A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GIST

Conditions: Gastrointestinal Stromal Tumor (GIST)
NCT02685046

Terminated

Imatinib as Pre-operative Anti-Colon Cancer Targeted Therapy

Conditions: Colonic Neoplasms
NCT03688568

Withdrawn

Study of Imatinib in Children With Neurofibromatosis and Airway Tumors

Conditions: Neurofibroma, Plexiform
NCT04598009

Recruiting

Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma

Conditions: Melanoma Stage III; Melanoma Stage IV
NCT01795716

Completed

Bioequivalence Study of Mesylate Imatinib Capsule in Chronic Myeloid Leukemia Body

Conditions: Chronic Myeloid Leukemia
NCT02495519

Completed

A Trial of Imatinib for Patients With Aggressive Desmoid Tumor (Aggressive Fibromatosis)

Conditions: Fibromatosis
NCT00858806

Completed

Intermittent Imatinib Treatment in Chronic Myeloid Leukemia and Philadelphia Chromosome (Ph+CML) Patients Who Achieved a Complete Cytogenetic Response (CCgR) on Standard Imatinib Therapy

Conditions: Chronic Myeloid Leukemia
NCT00424515

Completed

Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma

Conditions: Mucosal Melanoma; Acral/Lentiginous Melanoma; Chronically Sun Damaged Melanomas
NCT01151852

Completed

Rechallenge of Imatinib in GIST Having no Effective Treatment: RIGHT

Conditions: Gastrointestinal Stromal Tumors
NCT02461849

Recruiting

Patients With Refractory, Metastatic Cancer Harboring KIT Mutation or Amplification to Investigate the Clinical Efficacy and Safety of Imatinib Therapy

Conditions: Advanced, Refractory Cancer
NCT01297777

Completed

Imatinib in KIT-negative Systemic Mastocytosis

Conditions: Systemic Mastocytosis
NCT02317159

Unknown status

Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia

Conditions: Chronic Myeloid Leukemia
NCT01819389

Completed

Low-dose Nilotinib and Imatinib Combination in Chronic Myeloid Leukemia Patients, With Failure, Suboptimal Response or Treatment Intolerance

Conditions: Leukemia, Myeloid, Chronic, BCR-ABL Positive
NCT03469011

Recruiting

A Study to Try to Bring Back Radioiodine Sensitivity in Patients With Advanced Thyroid Cancer.

Conditions: Papillary Thyroid Cancer
NCT02272777

Completed

A Study of Imatinib and Nilotinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase

Conditions: Leukemia
NCT04416750

Recruiting

Positioning Imatinib for Pulmonary Arterial Hypertension

Conditions: Pulmonary Arterial Hypertension
NCT03722420

Recruiting

Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China)

Conditions: Chronic Myeloid Leukemia, Chronic Phase